article
The term nociplastic pain refers to pain arising from altered central nervous system processing, without evidence of tissue or nerve damage.
Recent News
Dr. Cush reviews best reasons to go to ACR annually, but also the best way to learn ACR26 content this year.Read Article
Dr. John Cush
Tweet
Why Did the Last Drug Fail?
When a patient fails a drug, we tend to consider what will be the next drug. Most of our clinics have patients on their second or third advanced therapy. Drug failure has become more common, not less. A question that we too rarely write in the notes https://t.co/r5mQjI79iQ
Dr. John Cush
Tweet
Looking for RA-ILD: 9 Clinical Clues from ANCHOR-RA
Which of our RA patients will develop RA-ILD, and how can we better identify these patients? In abstract #2884 at #ACR26 , Dr. Jeffrey Sparks presented findings from ANCHOR-RA trial, a large prospective cross-sectional study https://t.co/P96KAcPmWt
David Liew
Tweet
It was a beautiful Year in Preview from @AlexisOgdie - here's a summary of her take on what might be to come in rheumatology in the year ahead
#ACR26 @RheumNow https://t.co/DneNoUkc7u https://t.co/jlAdwZYAQI
Dr. John Cush
Tweet
Making the Case for Early Biologics in Lupus
A new diagnosis of SLE can be overwhelming for patients. The decision to initiate biologic versus non-biologic therapy early in the disease course may have far-reaching implications for disease control, glucocorticoid exposure, and https://t.co/CmTeHTwzZw
Dr. John Cush
Tweet
ACR 2026 Rheumatology Round Up https://t.co/ZpvYJRZvn0
Dr. John Cush
Tweet
ACR 2026 Day 3 Report
https://t.co/7DbbFhEtp4 https://t.co/tCB9tKgTup
Dr. John Cush
Tweet
Dr. John Cush
Tweet
Pregnancy After CAR-T in Autoimmune Disease: 14 Pregnancies, No Flares
The first multicenter series of pregnancies after CAR T-cell therapy for autoimmune disease reports 8 healthy births and no maternal flares. It is the first dataset of its kind, and the numbers are small. https://t.co/uqWz8GeAmX
Dr. John Cush
Tweet
Menopause and Rheumatoid Arthritis: Are we asking enough?
A study from Mayo Clinic at ACR Convergence, abstract 1849 examines menopause symptom burden in women with and without RA. Using two research datasets, Kristen Young and colleagues conducted a cross-sectional analysis of https://t.co/V3VJXo3z5w
Dr. John Cush
Tweet
Beyond HLA-B27: Anti-14-3-3eta Autoantibodies as a Candidate Marker in axSpA
14-3-3 proteins are a conserved family of seven isoforms with diverse cellular functions, found predominantly intracellularly. The 14-3-3eta isoform has been studied as a proinflammatory mediator in RA https://t.co/yC4bhtnTCD
Dr. John Cush
Tweet
PMR: Spare The Steroids Please
Steroids remain both the cornerstone and the Achilles' heel of PMR management. We have aspirations of briskly tapering our patients once they have had their honeymoon phase with prednisone. But when Ms. Jones calls you with a reported second PMR https://t.co/dbrdVZRuoN
Dr. John Cush
Tweet
All RA-ILD deserves a trial of immunomodulation
The optimum treatment approach in RA-ILD remains an area mired in controversy. This is evident from the contrasting views taken by the 2 recent expert guidelines from ACR and EULAR, which advocate for very different treatment https://t.co/vxr8NDruGI
Dr. John Cush
Tweet
IgG4-RD in 3 Talks: Shorter Steroids, Earlier B-Cell Therapy
IgG4-related disease now has two phase 3 trials and its first dedicated treatment guidelines. Glucocorticoids remain the weak point.
https://t.co/pWu1eoiMVG https://t.co/yXXk0R4Rbs
Dr. John Cush
Tweet
New Treatment for Fibromyalgia? Will It Help or Harm?
For years, the pharmacologic treatment landscape for fibromyalgia has remained relatively unchanged, with limited therapeutic options despite a substantial disease burden. This condition is characterized by chronic https://t.co/nn9wu7xibY
Dr. John Cush
Tweet
Biologic Dosing and Obesity
A 46-year-old with pSa and a BMI of 38 still has active disease on adalimumab (Humira) 40 mg every other week. What do you do? Stephen Balevic, MD, PhD, discusses this question in "Prescribing the Right Dose: How Obesity Alters Drug https://t.co/0SGQGs32U2
Dr. John Cush
Tweet
One Diagnosis, Different Diseases: Is TLR7/8 Inhibition the Future of Lupus Treatment?
We call it systemic lupus erythematosus (SLE), but are we really treating one disease? Increasingly, I wonder whether grouping biologically distinct patients under one diagnosis is limiting https://t.co/30MGwIRUgO
Dr. John Cush
Tweet
Cardiovascular Risk in Rheumatoid Arthritis
What is the link between cardiovascular risk and dementia?
In abstract 1454, Michelle Allen and colleagues at Mayo Clinic studied 2,483 adults with incident RA diagnosed between 1980 and 2019. Patients were followed for Alzheimer’s https://t.co/JaITrlZXIt
Dr. John Cush
Tweet
ACR 2026 – Day 2 Report
https://t.co/H5aJMSwHwk https://t.co/gzGSaA9czB
Video
Podcasts
Why I Go to ACR Convergence Every Year (11.13.2026)
ACR 2026 Daily Podcasts - Day4b
ACR 2026 RheumNow Day 4 Recap-
ACR 2026 Daily Podcasts - Day4a
Therapeutic Updates
Individualized PsA Treatment With an IL-23i or a JAKi
Sponsored by AbbVie Medical Affairs + Health Impact
In Part 2 of our PsA management series, Saakshi Khattri, MD, and Lindsay Tom, PA-C, discuss tailoring treatment for patients with multidomain PsA and how IL-23i and JAKi data guide their decisions
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
